Skip to content
Pass Duke Elder
Textbook / Chapter 12 / Orbit, eyelids, lacrimal system and oculoplastics

Thyroid eye disease

Thyroid eye disease is the commonest cause of proptosis in adults and the commonest orbital disease. It is an autoimmune inflammation of the orbital fat and eye muscles that runs a course of its own, separate from the thyroid gland. This lesson explains why the orbit swells, how activity and severity are judged, and why the treatment depends on which phase the patient is in.

9 minute read8 linked questions

What it is and who gets it

Thyroid eye disease (TED), also called Graves' orbitopathy, is an autoimmune inflammatory disease of the tissues behind the eye. It is tied to Graves' disease, the autoimmune cause of hyperthyroidism, but it is not caused by the high thyroid hormone level. Around 40 to 50% of people with Graves' disease develop some eye involvement, most of it mild, and the British Thyroid Foundation puts moderate to severe disease at about 5 to 6%.

About nine in ten patients are hyperthyroid at some point. The rest are euthyroid or hypothyroid, for example with Hashimoto's thyroiditis, so normal thyroid function tests do not exclude the diagnosis. The eye disease may appear before, with or after the thyroid disease. Women are affected several times more often than men, as with Graves' disease itself.

Smoking is the most important modifiable risk factor. It roughly doubles the chance of developing TED, and heavy smoking raises it about eightfold. Smokers also get more severe disease and respond less well to treatment. The other risk factors are uncontrolled thyroid function in either direction, high levels of TSH receptor antibodies, treatment with radioiodine and, in the 2021 European guideline, high cholesterol.

Why the orbit swells

The link between the thyroid and the orbit is a shared target. TSH receptor antibodies, which stimulate the thyroid in Graves' disease, also bind receptors on orbital fibroblasts, the connective tissue cells that lie between the muscle fibres and in the orbital fat. The receptor for insulin-like growth factor 1 (IGF-1) on the same cells takes part in the signalling, which is why a drug that blocks it works.

Activated fibroblasts do three things. They release signals that draw in T lymphocytes, sustaining the inflammation. They secrete glycosaminoglycans, large sugar chains that bind water, so the tissues swell. Some of them turn into fat cells, so the volume of orbital fat rises. The muscle fibres themselves are not the target: the muscles enlarge because the tissue between their fibres is swollen and later scarred.

The orbit is a bony cone, open only at the front. Extra volume inside it has three consequences. The globe is pushed forwards (proptosis). Venous drainage is squeezed, causing congestion and swollen lids and conjunctiva. At the narrow apex, enlarged muscles can crush the optic nerve. Each sign of the disease comes from one of these effects or from scarring of the muscles.

3D atlasThe four rectus muscles converge on the annulus of Zinn at the orbital apex, around the optic nerve. Swollen muscle bellies crowd the nerve here.

The clinical picture

Upper lid retraction is the commonest sign, present in up to 90% of patients: white sclera shows between the lid and the top of the cornea, giving a staring look. It has several causes, including sympathetic overaction of Müller's muscle, scarring of the levator, and the lid following an overacting superior rectus. Lid lag is the companion sign: on slow downgaze the upper lid trails behind the eye.

Proptosis is usually bilateral but often asymmetrical. TED is the commonest cause of both bilateral and unilateral proptosis in adults. With retracted lids and a forward globe, the eye cannot close fully and the cornea dries: grittiness, watering and photophobia are the commonest symptoms, and severe exposure keratopathy can ulcerate.

Restrictive myopathy causes diplopia. A swollen, then fibrosed, muscle cannot stretch, so the eye is tethered towards the affected muscle and cannot move away from it. The muscles are affected in a typical order: inferior rectus, medial rectus, superior rectus, then lateral rectus. A tight inferior rectus therefore limits upgaze, and a tight medial rectus limits abduction, which can mimic a sixth nerve palsy. On CT or MRI the muscle bellies are enlarged but the tendons are spared, which distinguishes TED from orbital myositis, in which the tendon is thickened too.

Soft tissue signs of inflammation are lid swelling and redness, conjunctival redness, chemosis (conjunctival oedema) and swelling of the caruncle.

Activity and severity are different questions

TED runs a predictable course, described by Rundle's curve. An active (inflammatory) phase lasts roughly 6 to 18 months, sometimes up to two years, during which the signs worsen and then plateau. It is followed by an inactive (fibrotic) phase in which the inflammation has burnt out, some improvement occurs, and what is left is permanent: proptosis, scarred muscles and retracted lids.

This matters because the two phases need opposite treatment. Immunosuppression only works while there is inflammation to suppress. Surgery is only predictable once the disease has stopped changing. So two separate questions are asked at every visit: how active is the disease, and how severe is it.

Activity is scored with the Clinical Activity Score (CAS), one point for each of seven features. A score of 3 or more out of 7 indicates active disease. At follow-up visits three further points are available for an increase in proptosis, a decrease in eye movement and a fall in acuity over the preceding one to three months.

  1. Spontaneous pain or pressure behind the eye.
  2. Pain on eye movement.
  3. Redness of the eyelids.
  4. Redness of the conjunctiva.
  5. Swelling of the eyelids.
  6. Chemosis.
  7. Swelling of the caruncle.
ClassWhat it meansUsual approach
MildMinor lid retraction, soft tissue signs or proptosis with little effect on daily lifeRisk factor control, lubricants, selenium, watch
Moderate to severeEnough lid retraction, proptosis, soft tissue involvement or diplopia to affect daily life, without threat to sightImmunosuppression if active; rehabilitative surgery if inactive
Sight-threateningDysthyroid optic neuropathy or corneal breakdownUrgent treatment
Severity of thyroid eye disease (EUGOGO classes)

Dysthyroid optic neuropathy

Dysthyroid optic neuropathy (DON) is compression of the optic nerve at the orbital apex by enlarged muscles. It affects fewer than 5% of patients but is the main route to permanent blindness. It is often seen in eyes with little proptosis: a tight orbit that cannot decompress itself by pushing the globe forward transmits the pressure to the nerve instead.

The loss of vision is gradual and easily missed. The features to look for at every visit are reduced colour vision, which can change while acuity is still good, reduced acuity, a relative afferent pupillary defect if the disease is asymmetrical, and a visual field defect. The optic disc may be swollen, pale or entirely normal, so a normal disc does not exclude it.

DON is an emergency. European (EUGOGO) guidance is high-dose intravenous methylprednisolone straight away, with urgent surgical orbital decompression if the response is absent or poor. The other sight-threatening complication, corneal breakdown from exposure, is treated with intensive lubrication and urgent measures to cover the cornea.

Treatment by phase

Some measures apply to everyone. Stop smoking. Restore and keep normal thyroid function, avoiding swings in either direction. Use lubricants for exposure, raise the head of the bed for morning swelling, and use prisms for diplopia. Radioiodine can worsen TED, particularly in smokers, so antithyroid drugs are preferred while the eye disease is active and moderate to severe or sight-threatening. When radioiodine is used in a patient with mild active disease or other risk factors, a prophylactic course of low-dose oral prednisolone is given.

For mild active disease, a six-month course of selenium (100 micrograms twice daily) is advised. EUGOGO recommends it particularly where dietary selenium is low. Most mild disease settles with these measures alone.

For moderate to severe active disease the first-line treatment is intravenous methylprednisolone, which is more effective and better tolerated than oral steroid. The standard course is weekly infusions for 12 weeks, 500 mg for six weeks then 250 mg for six weeks, a cumulative dose of 4.5 g. The 2021 EUGOGO guideline recommends combining it with mycophenolate as first-line treatment, and allows a higher cumulative dose of steroid alone, up to 7.5 g, for the most severe cases. Cumulative doses above 8 g have been linked to severe liver injury, so liver function is monitored. Steroids reduce inflammation and pain but do little for proptosis.

Second-line options include a further course of steroid, orbital radiotherapy (typically 20 Gy in 10 fractions), ciclosporin or azathioprine with oral steroid, rituximab, tocilizumab and teprotumumab, a monoclonal antibody against the IGF-1 receptor that reduces proptosis. Availability of the newer biologics varies between health systems.

Once the disease has been inactive and stable for some months, rehabilitative surgery is offered in a fixed order, because each step alters the next.

  1. Orbital decompression: removing bone from the orbital walls, and sometimes fat, so the contents expand into the sinuses and the globe moves back. It changes eye alignment, so it comes first.
  2. Strabismus surgery: recessing the tight muscles to restore single vision. Moving the vertical recti changes lid position, so it comes second.
  3. Lid surgery: lowering retracted upper lids and removing excess skin and fat, last.

Summary

  • Thyroid eye disease is an autoimmune orbital inflammation driven by TSH receptor antibodies acting on orbital fibroblasts.
  • Fibroblasts make water-binding glycosaminoglycans and new fat, expanding the muscles and fat inside a rigid orbit.
  • About 10% of patients are euthyroid or hypothyroid, so normal thyroid tests do not exclude it.
  • Smoking is the strongest modifiable risk factor; radioiodine can worsen the disease.
  • Lid retraction is the commonest sign, and TED is the commonest cause of unilateral and bilateral proptosis in adults.
  • Muscles are affected in the order inferior, medial, superior, lateral rectus, with sparing of the tendons on imaging.
  • A Clinical Activity Score of 3 or more out of 7 indicates active disease; severity is graded separately.
  • Dysthyroid optic neuropathy presents with reduced colour vision and can occur with little proptosis; it needs urgent intravenous methylprednisolone and decompression if that fails.
  • Moderate to severe active disease is treated with weekly intravenous methylprednisolone to a cumulative 4.5 g; mild active disease with selenium.
  • Rehabilitative surgery waits for inactive disease and goes in order: decompression, strabismus, lids.

Check yourself

Quick recall on this lesson. These are easier than the question bank.

1. Which extraocular muscle is usually affected first in thyroid eye disease?
2. What Clinical Activity Score, out of 7, is the threshold for active disease?
3. A patient with inactive thyroid eye disease needs three operations. Which is done first?
4. Which symptom should raise suspicion of dysthyroid optic neuropathy?
Practise 8 questions on this lesson

Written for revision. It is not a source of clinical advice, and guidance changes.